drugset / Trial / NCT02731560
Rituximab (RTX) for Disease Modifying Anti Rheumatic Drug (DMARD) Non-responders in Pakistan: The Pakistan Rituximab Study (PARIS)
Phase 4
Completed
74 enrolled
Prof. Abid Z. Farooqi
Aga Khan University · collabFatima Memorial Hospital · collabFauji Foundation Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
A study to determine the efficacy and safety of rituximab in Pakistani patients with rheumatoid arthritis (RA) who have been inadequately controlled with standard disease modifying anti rheumatic drugs (DMARDs).
Timeline
- Start
- 2010-01
- Primary completion
- 2011-07
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | 1 g | Intravenous |